The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis

Journal of the American Academy of Dermatology

Volumn 49, Issue 1, 2003, Pages 79-82

  Housman, Salam Tamara ^a   Keil, Kimberly A ^a   Mellen, Beverly G ^a   McCarty, Martha A ^a   Fleischer Jr , Alan B ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; PYRITHIONE ZINC;

ADULT; AEROSOL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; ERYTHEMA; FEMALE; FOAM; FOLLOW UP; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN MANIFESTATION;

EID: 0038386277     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.417     Document Type: Article

References (10)

1. Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 2000; 39:41-4.
2. Lebwohl M, Ali S. Treatment of psoriasis, part 1: topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.
3. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-3.
4. Smith K. Skin cap: what have we learned, and when did we learn it? [editorial]. Dermatol Online J 1997;3:11 c.
5. Danielsen M, Hinck L, Ringold GM. Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor. Cell 1989;57: 1131-8.
6. Van de Kerkhof PC, De Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200: 292-8.
7. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24:443-7.
8. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000;39:521-38.
9. Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia: Saunders; 2001. p. 651.
10. Tan JKL. Pustular psoriasis and hepatotoxicity associated with use of Skin Cap. Dermatol Online J 1997;3:11d.